Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention

Ahn, Kye Taek; Seong, Seok-Woo; Choi, Ung Lim; Jin, Seong Eun; Kim, Jun Hyung; Lee, Jae‐Hwan; Choi, Si Wan; Jeong, Myung Ho; Chae, Shung Chull; Kim, Young Jo; Kim, Chong Jin; Kim, Hyo–Soo; Cho, Myeong Chan; Gwon, Hyeon‐Cheol; Jeong, Jin‐Ok; Seong, In‐Whan

doi:10.1097/md.0000000000014833

Cited by 22 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The total population was distributed based on BMI into different groups 16 i.e., Underweight (< 18.5), Healthy (18.5-24.9), Over weight (25.0-29.9), Obese (>30). Distribution of patients that were found to be in Healthy group are (32% in Ticagrelor & 28% in Prasugrel), Over weight (36% in Ticagrelor & 44% in Prasugrel), Obese (32% in Ticagrelor & 26% in Prasugrel).…”

Section: Discussionmentioning

confidence: 99%

Comparative Non-Randomised Observational Study of Prasugrel and Ticagrelor in Patients Undergoing Percutaneous Coronary Intervention

S¹,

Shravya²,

Divya³

et al. 2020

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Percutaneous Coronary Intervention (PCI) is the primary guideline-recommended treatment strategy for patients presenting with CAD, STEMI, NSTEMI, Unstable Angina. It is known that, the use of oral P2Y12 receptor antagonists (Prasugrel and Ticagrelor) in PCI patients could lead to improved outcomes compared with clopidogrel. This study has been designed for review and analysis of clinical safety and outcomes of these agents in patients undergoing PCI. Out of 100 patients (50 in Prasugrel group & 50 in Ticagrelor group) considered for the study, the incidence of stroke, stent thrombosis was comparable between the groups with P =0.044, P =0.041 respectively and was not comparable for MI (P=0.245). Single Death was reported. The results differed significantly for Palpitations/Arrhythmia(P=0.018), SOB(P=0.000), Dizziness(P=0.005), Creatinine levels(P=0.000), Fatigue(P=0.003), Headache(P=0.000) and did not differ significantly for Bleeding and Back pain in both the drug groups with P =1.000, P =0.438 respectively. Also, majority of the patients showed decreased platelet count in both the drug groups. Withdrawal parameters, like withdrawal due to cost(P=0.172) and withdrawal due to fear of side effects(P=1.000) when evaluated for both the drugs showed no significant difference. Outcomes associated with Prasugrel were not superior to outcomes associated with Ticagrelor when 30 days to 6 months follow up was done. The clinical safety, side effects and withdrawal parameters were comparable and the results showed no significant difference between these drug groups. Keywords: Percutaneous Coronary Intervention, Ticagrelor, Prasugrel, Dual Anti-Platelet therapy, Acute Coronary Syndrome, Coronary Artery Disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Non-Randomised Observational Study of Prasugrel and Ticagrelor in Patients Undergoing Percutaneous Coronary Intervention

S¹,

Shravya²,

Divya³

et al. 2020

J. Drug Delivery Ther.

View full text Add to dashboard Cite

show abstract

“…Estes resultados corroboram os dados atuais disponíveis na literatura, que indicam baixa ocorrência de eventos cerebrovasculares periprocedimento, mesmo no contexto de aumento na proporção de pacientes de maior complexidade. [7][8][9][10][11][12][13] Estudo publicado por Werner et al avaliou 46.888 pacientes submetidos à ICP e encontrou incidência de 0,4% de eventos cerebrovasculares. 11 Esta incidência ligeiramente superior provavelmente se deve ao fato do referido estudo apresentar amostra significativamente maior em relação ao número de pacientes avaliados em nosso estudo, além de…”

Section: Discussionunclassified

“…Este número superior de AVC em relação ao nosso estudo pode ser explicado pelo fato do registro ter incluído um perfil de pacientes mais complexos em sua análise, portadores de diabetes com IAM e submetidos à ICP. 12 Em nossa série, as comorbidades mais frequentes no grupo de pacientes que apresentou evento cerebrovascular foram hipertensão, diabetes, dislipidemia e tabagismo, características semelhantes às da população de estudos prévios. 11,14 Nenhuma variável clínica foi associada a um maior risco de evento quando comparamos a amostra de pacientes do Grupo Evento Cerebrovascular com o Controle no nosso estudo.…”

Section: Journal Of Transcatheter Interventionsunclassified

“…Uma justificativa plausível para o ocorrido pode ser o fato de um número considerável de pacientes ter apresentado AIT como evento, associado a um perfil menos complexo de pacientes, quando comparado a outros estudos mais robustos, que incluíram apenas pacientes com IAM e/ou diabetes em suas amostras. 7,8,11,12,20 Assim como no período intra-hospitalar, o seguimento de 30 dias da nossa amostra apontou incidência de mortalidade, sequelas e prejuízo funcional inferior ao encontrado na literatura atualmente. 7,8,[11][12][13][14][15]20 É possível que a proporção relativamente alta de AIT em nossa população (em comparação com AVCs) tenha contribuído para o melhor prognóstico em nossa série.…”

Section: Journal Of Transcatheter Interventionsunclassified

See 1 more Smart Citation

Cerebrovascular event after cardiac catheterization in the modern era: prevalence, in-hospital clinical course, and 30-day follow-up

Alves¹,

Fazzio²,

Júnior³

et al. 2019

J Transcat Intervent

View full text Add to dashboard Cite

show abstract

“…Type 2 diabetes mellitus (T2DM) has been established as an important risk factor for adverse outcomes in patients with acute coronary syndrome (ACS) [1][2][3]; this may be due to a rapid development of atherosclerosis related to T2DM [4]. T2DM patients with ACS remain at a very high residual risk of adverse cardiovascular (CV) events and mortality, despite receiving percutaneous coronary intervention (PCI) and guideline-recommended rst-line medication therapies [5][6][7][8]. Therefore, further risk assessment of such patients may help better determine prognosis and guide better medical management.…”

Section: Introductionmentioning

confidence: 99%

Prognostic impact of atherogenic index of plasma (AIP) in type 2 diabetes mellitus patients with acute coronary syndrome undergoing percutaneous coronary intervention

Sun

Cheng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The association of atherogenic index of plasma (AIP), an emerging lipid index which can predict risk for cardiovascular (CV) disease, with adverse outcomes in type 2 diabetes mellitus (T2DM) patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) has been undetermined. Therefore, the aim of this study was to investigate whether AIP could independently predict adverse CV events in T2DM patients with ACS undergoing PCI.Methods: This study was a retrospective analysis of a single-centre prospective registry involving 826 consecutive T2DM patients who underwent primary or elective PCI for ACS at our CV center from June 2016 to November 2017. This study eventually included 798 patients (age, 61±10 years, male, 72.7%). AIP was calculated as the base 10 logarithm of the ratio of plasma concentration of triglycerides to high density lipoprotein-cholesterol (HDL-C). All patients were divided into 4 groups based on the AIP quartiles. The primary endpoint was a composite of all-cause death, non-fatal ischemic stroke, non-fatal myocardial infarction (MI), or unplanned repeat revascularization. The key secondary endpoint was a composite of cardiovascular death, non-fatal ischemic stroke, or non-fatal MI.Results: During a median follow-up period of 927 days, 198 patients developed at least one event. An unadjusted Kaplan–Meier analysis showed the incidence of the primary endpoint increased gradually with rising AIP quartiles (log-rank test, P =0.001). A multivariate Cox proportional hazards analysis revealed that compared with the lowest AIP quartile, the top AIP quartile was associated with significantly increased risk for the primary and key secondary endpoints (hazard ratio [HR]: 2.153; 95% confidence interval [CI]: 1.355 to 3.421; P =0.001, and HR: 2.613; 95% CI: 1.024 to 6.666; P =0.044, respectively). Inclusion of AIP quartiles in a baseline prediction model for the primary endpoint increased the Harrell’s C statistic from 0.697 to 0.707. More importantly, addition of AIP quartiles to the above model significantly improved the continuous net reclassification improvement (continuous NRI =19.1%, P <0.001).Conclusions: A higher AIP value on admission was independently and strongly associated with adverse CV events in T2DM patients with ACS undergoing PCI.

show abstract

Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention

Abstract: Supplemental Digital Content is available in the text

Cited by 22 publications

References 30 publications

Comparative Non-Randomised Observational Study of Prasugrel and Ticagrelor in Patients Undergoing Percutaneous Coronary Intervention

Comparative Non-Randomised Observational Study of Prasugrel and Ticagrelor in Patients Undergoing Percutaneous Coronary Intervention

Cerebrovascular event after cardiac catheterization in the modern era: prevalence, in-hospital clinical course, and 30-day follow-up

Prognostic impact of atherogenic index of plasma (AIP) in type 2 diabetes mellitus patients with acute coronary syndrome undergoing percutaneous coronary intervention

Contact Info

Product

Resources

About